Huntington Disease
📧 Sign up to get email alerts when something new happens for Huntington Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-05-19FDA Approved: TETRABENAZINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for tetrabenazine from Apotex Corp.
-
FDA approval · 2023-02-17FDA Approved: AUSTEDO XR — Original Application (Teva Neuroscience, Inc.)
FDA approved AUSTEDO XR (deutetrabenazine) from Teva Neuroscience in an original NDA; the extended-release formulation targets symptoms of H…
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease [Phase 2]
Phase 2 open-label study of ANX005 in subjects with or at risk for Huntington's disease has completed.
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients. [Phase 2, Phase 3]
A clinical extension study is being conducted to evaluate safety and efficacy of Cellavita-HD in Huntington's disease patients across Phase …
-
CLINICAL_TRIALS trial_result · 2022-09-02Clinical Trial Update: A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) [Phase 4]
A Phase 4 pilot trial evaluating impulsivity in Huntington's disease patients treated with Xenazine (tetrabenazine).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-05-02Clinical Trial Update: A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi [Phase 2]
Phase 2 study in Huntington's disease evaluating safety, tolerability, pharmacokinetics, and efficacy of Pepi has completed.
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease [Phase 1, Phase 2]
Phase 1/2 trial of WVE-120102 in Huntington's disease was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-04-06Clinical Trial Update: Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease [Phase 2]
Phase 2 within-subject crossover trial of neflamapimod in early-stage Huntington disease; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease [Phase 1, Phase 2]
A combined Phase 1/2 trial assessing safety and tolerability of WVE-120101 in Huntington's disease was terminated with results posted in 202…
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease [Phase 2]
Open-label extension study results for pridopidine (ACR16) in symptomatic treatment of Huntington disease (Phase 2) completed; results poste…
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease [Phase 1, Phase 2]
Open-label extension study evaluating safety and tolerability of WVE-120102 in Huntington's disease; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease [Phase 1, Phase 2]
Open-label extension study evaluating safety and tolerability of WVE-120101 in Huntington's disease was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2021-11-16Clinical Trial Update: A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease [Phase 1]
Phase 1 study evaluating sigma-1 and D2 receptor occupancy by pridopidine in healthy volunteers and Huntington's disease patients; completed…
-
CLINICAL_TRIALS trial_result · 2021-09-17Clinical Trial Update: A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease [Phase 2]
Phase 2 trial evaluating pridopidine in Huntington's disease; the study is terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-09Clinical Trial Update: The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease [NA]
A completed clinical trial assessing the effects of video game–based exercise on dynamic balance and gait in individuals with Huntington's d…
-
CLINICAL_TRIALS trial_result · 2021-07-19Clinical Trial Update: A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease [Phase 2]
Phase 2 trial evaluating pridopidine versus placebo for symptomatic treatment in Huntington's disease completed with posted results.
-
FDA approval · 2021-02-09FDA Approved: AUSTEDO — Supplemental Application (Teva Neuroscience, Inc.)
The FDA approved a supplemental application for Austedo (deutetrabenazine) from Teva Neuroscience, Inc., indicating an approved update to th…
-
CLINICAL_TRIALS trial_result · 2021-01-19Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) [Phase 2]
A Phase 2 trial evaluating safety, tolerability, PK, and PD of RO7234292 (ISIS 443139) in Huntington's disease patients who participated in …
-
FDA approval · 2021-01-06FDA Approved: TETRABENAZINE — Supplemental Application (Precision Dose Inc.)
FDA has approved a supplemental application for tetrabenazine from Precision Dose Inc.
-
CLINICAL_TRIALS trial_result · 2021-01-05Clinical Trial Update: Study of Memantine to Treat Huntington's Disease [Phase 4]
A Phase 4 trial evaluating memantine for Huntington's disease has completed with results posted in 2021.
-
FDA approval · 2021-01-04FDA Approved: TETRABENAZINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for tetrabenazine filed by Sun Pharmaceutical Industries, Inc. This action expands the approved …
-
FDA approval · 2021-01-04FDA Approved: TETRABENAZINE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for tetrabenazine from Camber Pharmaceuticals, Inc., enabling a generic version to be marketed. This…
-
FDA approval · 2020-12-04FDA Approved: TETRABENAZINE — Original Application (Ajanta Pharma USA Inc.)
FDA approved an Original Application for a generic tetrabenazine from Ajanta Pharma USA Inc.
-
FDA approval · 2020-12-02FDA Approved: AUSTEDO — Supplemental Application (Teva Neuroscience, Inc.)
FDA approves a supplemental application for Austedo (deutetrabenazine) from Teva Neuroscience, Inc.
-
CLINICAL_TRIALS trial_result · 2020-04-20Clinical Trial Update: Electronic-health Application To Measure Outcomes REmotely Clinical Trial [NA]
A completed clinical trial using an electronic health application to measure outcomes remotely in neurodegenerative disease contexts, with r…